Leishmania initially activates but subsequently down-regulates intracellular mitogen-activated protein kinases and nuclear factor-kappaB signaling in macrophages

Molecular Immunology
Rym Ben-OthmanKoussay Dellagi

Abstract

The complex interactions between Leishmania and macrophages are central to the outcome of parasite infection. Disrupting signaling molecules to impair macrophage function, is a subversive strategy used by several pathogens. In the present study, we show that the initial contact of Leishmania with human naïves macrophages and murine Raw264.7 macrophage cell line induced a rapid and transient activation of extracellular-signal-regulated kinases 1 and 2 (ERK1/2) and p38MAPK. This activation is an actin-dependent mechanism that requires internalization of live parasites. Once stably infected, macrophages become unresponsive to subsequent parasite infection. Priming of cells with IFNgamma, prior to Leishmania infection, did not prevent the silencing of MAPKs pathways induced by Leishmania parasites. NF-kappaB transcriptional activity in response to Leishmania infection is also impaired in stably infected cells. This impairment was not due to MAPK deactivation as inhibition of ERK1/2 and p38MAPK, actually enhances the transcriptional activity of NF-kappaB in response to initial contact of Leishmania with the murine macrophagic cell line Raw264.7. Moreover, Leishmania parasites could not reverse the hyporesponsive state induced by LPS...Continue Reading

References

May 18, 1999·The Journal of Surgical Research·J KraatzM A West
Jan 10, 2002·Critical Care Medicine·Michael A West, Wyrta Heagy
Nov 5, 2003·Gene·Shen-Hsi YangAlan J Whitmarsh
Feb 4, 2006·Progress in Lipid Research·Deborah H Anderson

❮ Previous
Next ❯

Citations

Feb 12, 2011·Science·Annette IvesSlavica Masina
Mar 9, 2010·Journal of Inflammation·Nicholas J Lapara, Ben L Kelly
Aug 21, 2012·International Journal of Medical Microbiology : IJMM·Katharina ReinhardAlexander Visekruna
Jan 3, 2016·Ticks and Tick-borne Diseases·A E Lew-Tabor, M Rodriguez Valle
Aug 18, 2009·Molecular Immunology·Rym Ben-OthmanLamia Guizani-Tabbane
Aug 31, 2011·International Immunopharmacology·Piu SahaMitali Chatterjee
Aug 29, 2009·Immunology Letters·Teresa C Calegari-SilvaUlisses G Lopes
Nov 1, 2016·The Journal of Immunology : Official Journal of the American Association of Immunologists·Valentin SchatzJonathan Jantsch
Sep 26, 2014·PLoS Neglected Tropical Diseases·Iris J Gonzalez-LealHeidrun Moll
Jul 13, 2011·Nature Reviews. Microbiology·Paul Kaye, Phillip Scott
Jul 18, 2014·Journal of Leukocyte Biology·Nancy McCartney-FrancisSharon M Wahl
Aug 23, 2011·Molecular and Cellular Biochemistry·Ankita SrivastavaRakesh K Singh
Nov 22, 2019·Frontiers in Immunology·Niels-Arne MünckJan Ehrchen
Oct 31, 2018·Frontiers in Microbiology·Rosana SousaAlbert Schriefer
Mar 10, 2018·Frontiers in Immunology·Valentin SchatzJonathan Jantsch
Jun 1, 2021·Frontiers in Cellular and Infection Microbiology·Tainá CavalcanteBeatriz Simonsen Stolf

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.